FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
Anti-[18F]FACBC PET-CT for the Characterization of Primary Prostate Cancer
The purpose of this research project is to test if a compound (chemical substance) has a natural tendency to go to prostate cancer. This compound has a small amount of radioactivity attached to it and is called a radiotracer. The name of the radiotracer is FACBC and can be detected on a special imaging device called a PET scanner (positron emission tomography). The radiotracer is treated in the body much like an amino acid which is a nutrient required for normal functioning. Tumors also use these nutrients. Earlier studies have shown that this radiotracer may be able to detect prostate cancer.
The investigators will perform a study with 20 patients in whom they know have prostate cancer after a biopsy and who are scheduled for an operation in which the prostate is removed and the nearby lymph nodes are examined. This operation is called prostatectomy. The investigators think that this radiotracer can help us determine where exactly the prostate cancer is present in the prostate or if it has spread. This information may be useful in the future to help with other non-surgical therapy such as radiation beam therapy.
The investigators will compare the results of the FACBC PET scan to the results of the pathology analysis of the removed prostate. In this way the investigators can determine how good a test FACBC PET is for finding out where and if prostate cancer is located in the prostate or nearby lymph nodes. The investigators will also do more advanced analysis on the biopsy samples to see if they can tell why FACBC goes into prostate cancer cells.
This radiotracer has been tested in over 100 human subjects without incident. It has also been chosen by the National Institutes of Health (NIH) as a promising radiotracer. The NIH is funding this study.
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients must be 18 years of age or older.
- Patients will be scheduled for prostatectomy based on a diagnosis of primary prostate cancer.
- Ability to lie still for PET scanning
- Patients must be able to provide written informed consent.
Exclusion Criteria:
- Age less than 18
- Inability to lie still for PET scanning
- Cannot provide written informed consent.
- Less than 4 weeks since any prior prostate biopsy (to decrease false positive uptake from inflammation).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: FACBC Imaging
Dynamic FACBC PET of primary prostate carcinoma.
|
Anti[18F]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Diagnostic Performance Per Sextant at Each Time Point by Visual Analysis
Periodo de tiempo: At 4, 16, 28 and 40 minutes post-injection of FACBC
|
Each of 12 sextants per prostate (for a total of 120 sextants for the 10 patients) were analyzed separately at 4, 16, 28 and 40 min post-injection for the presence or absence of focal activity suspicious for tumor. Sensitivity: Proportion of people with a disease who have a positive test result Specificity: The proportion of people without disease who have a negative test result Positive Predictive Value (PPV):The probability that a person who has a positive test result has the disease for which the test was conducted. Negative Predictive Value (NPV): The probability that a person who has a negative test result does not have the disease for which the test was conducted Accuracy: Ability of the test to differentiate between disease and non-disease. Note: 'n=' is the denominator used to compute each parameter. |
At 4, 16, 28 and 40 minutes post-injection of FACBC
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mean SUVmax of Low Versus High Gleason Groups
Periodo de tiempo: 4 minutes,16 minutes,28 minutes and 40 minutes
|
To determine id radiotracer uptake correlates with gleason score
|
4 minutes,16 minutes,28 minutes and 40 minutes
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: David M Schuster, MD, Emory University
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRB00008094
- FACBC (Otro identificador: Other)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre anti [18F]FACBC
-
David M. Schuster, MDTerminado
-
Bital Savir-BaruchBlue Earth DiagnosticsDesconocidoCáncer de cuello uterino | Cáncer epitelial de ovario | Cáncer endometrialEstados Unidos
-
Blue Earth DiagnosticsTerminadoNeoplasias prostáticasEstados Unidos, Italia, Noruega
-
University of OxfordBlue Earth DiagnosticsTerminado
-
Mayo ClinicBlue Earth Diagnostics, IncReclutamientoNeoplasia maligna intracraneal metastásica | Neoplasia Intracraneal RecurrenteEstados Unidos
-
Blue Earth DiagnosticsAmerican College of Radiology; Syne Qua Non Limited; IND 2 Results LLCTerminadoCancer de prostataEstados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminadoCarcinoma de próstata metastásico | Cáncer de próstata en estadio IVB AJCC v8Estados Unidos
-
National Taiwan University HospitalReclutamientoRecaída bioquímica de neoplasia maligna de próstataTaiwán
-
Emory UniversityNational Cancer Institute (NCI)Terminado
-
Blue Earth DiagnosticsSyne Qua Non Limited; Innovate UK; IND 2 Results LLCTerminadoCáncer de próstataReino Unido